Patents by Inventor Mehdi Rajabi

Mehdi Rajabi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11976092
    Abstract: Disclosed herein are high Tm RNA nanostructures that can be composed of one or more modules or motifs to build RNA nanostructures with or without layers. The RNA nanostructures can have a core domain and three or more double-stranded arms and formulations thereof to conjugate high copy numbers of therapeutics, pH responsive or enzyme cleavable drug cargo. Also described herein is a design strategy for generation of synthetic RNA oligonucleotides that can self assemble into highly thermostable RNA structures. Also described herein are uses of the RNA nanostructures described herein.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: May 7, 2024
    Assignees: Ohio State Innovation Foundation, University of Kentucky Research Foundation
    Inventors: Peixuan Guo, Mario Vieweger, Xin Li, Sijin Guo, Hongran Yin, Xijun Piao, Yi Shu, Dan Shu, Mehdi Rajabi
  • Patent number: 11351137
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Grant
    Filed: June 7, 2021
    Date of Patent: June 7, 2022
    Assignee: NANOPHARMACEUTICALS LLC
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Publication number: 20210299262
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 30, 2021
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Patent number: 11077082
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: August 3, 2021
    Assignee: NANOPHARMACEUTICALS, LLC
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Patent number: 10695436
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: June 30, 2020
    Assignee: NANOPHARMACEUTICALS, LLC
    Inventors: Shaker A. Mousa, Mehdi Rajabi
  • Publication number: 20190314314
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Application
    Filed: April 30, 2019
    Publication date: October 17, 2019
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Patent number: 10328043
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone ?v?3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: June 25, 2019
    Assignee: NANOPHARMACEUTICALS, LLC.
    Inventors: Shaker Mousa, Mehdi Rajabi, Ozlem O. Karakus
  • Publication number: 20190111145
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Application
    Filed: December 18, 2018
    Publication date: April 18, 2019
    Inventors: Shaker A. Mousa, Mehdi Rajabi
  • Patent number: 10201616
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 12, 2019
    Assignee: NANOPHARMACEUTICALS, LLC
    Inventors: Shaker A. Mousa, Mehdi Rajabi
  • Publication number: 20170348425
    Abstract: Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin ?v?3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 7, 2017
    Inventors: Shaker A. Mousa, Mehdi Rajabi